The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 178 of the 179 references it cites were found in a registry or an index.
Abstract
Cholinergic synapses are ubiquitous in the human central nervous system. Their high density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic transmission is likely to be critically important for memory, learning, attention and other higher brain functions. Several lines of research suggest additional roles for cholinergic systems in overall brain homeostasis and plasticity. As such, the brain's cholinergic system occupies a central role in ongoing research related to normal cognition and age-related cognitive decline, including dementias such as Alzheimer's disease. The cholinergic hypothesis of Alzheimer's disease centres on the progressive loss of limbic and neocortical cholinergic innervation. Neurofibrillary degeneration in the basal forebrain is believed to be the primary cause for the dysfunction and death of forebrain cholinergic neurons, giving rise to a widespread presynaptic cholinergic denervation. Cholinesterase inhibitors increase the availability of acetylcholine at synapses in the brain and are one of the few drug therapies that have been proven clinically useful in the treatment of Alzheimer's disease dementia, thus validating the cholinergic system as an important therapeutic target in the disease. This review includes an overview of the role of the cholinergic system in cognition and an updated understanding of how cholinergic deficits in Alzheimer's disease interact with other aspects of disease pathophysiology, including plaques composed of amyloid-β proteins. This review also documents the benefits of cholinergic therapies at various stages of Alzheimer's disease and during long-term follow-up as visualized in novel imaging studies. The weight of the evidence supports the continued value of cholinergic drugs as a standard, cornerstone pharmacological approach in Alzheimer's disease, particularly as we look ahead to future combination therapies that address symptoms as well as disease progression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The FDA approved two anti-amyloid immunotherapies, lecanemab and donanemab, for “early-stage” AD, encompassing both stage 3 (MCI) and stage 4 (mild dementia).”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [18]
In the citing paper
“Degeneration of cholinergic neurons is known to significantly contribute to cognitive decline in AD patients [132] and has been studied in a variety of genetic AD mouse models.”
From Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models (2020) · cites this paper as [132]
In the citing paper
“AChE contributes to acetylcholine depletion and may facilitate the formation of neurotoxic Aβ-AChE complexes38.”
From Small-molecule PCSK9 inhibition enhances BBB amyloid-β clearance and suppresses microglial inflammation in Alzheimer’s disease models (2026) · cites this paper as [38]
In the citing paper
“Cholinergic deficit also alters the permeability of the blood brain barrier causing erroneous transportation of metabolites and hampering the removal of amyloid plaque, worsening the disease condition [8].”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [8]
In the citing paper
“From this point of view, AD could be prevented or effectively treated by decreasing the production of Aβ and tau; preventing aggregation or misfolding of these proteins; neutralizing or removing the toxic aggregate or misfolded forms of these proteins; or a combination of these modalities.7”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [7]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Perry, E. K., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P. H., & Perry, R. H. (1978) · BMJ · doi:10.1136/bmj.2.6150.1457 · Cited by 2,042
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Human Memory and the Cholinergic System: A Relationship to Aging?
Drachman, D. A. (1974) · Archives of Neurology · doi:10.1001/archneur.1974.00490320001001 · Cited by 1,397
NEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311
Research works printed but not linked: 1
- Geula, 1994, Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease, 263
Cited by
Items 501–600 of 1,002
Luz, D. A., Pinheiro, A. M., Fontes-Júnior, E. A., & Maia, C. D. S. F. (2023) · Medicinal Research Reviews · doi:10.1002/med.21957 · Cited by 23
A Comprehensive Analysis on Galantamine Based Hybrids for the Management of Alzheimer's Disease
Singh, Y. P., Prasad, S., & Kumar, H. (2024) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70004 · Cited by 23
Yan, R., Wang, W., Yang, W., Huang, M., & Xu, W. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230314 · Cited by 23
Li, W., Shan, B., Cheng, X., He, H., Qin, J., Zhao, H., Tian, M., Zhang, X., & Jin, G. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101828 · Cited by 23
Peter, J., Mayer, I., Kammer, T., Minkova, L., Lahr, J., Klöppel, S., Grothe, M. J., & Orth, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-95573-8 · Cited by 23
Xu, Y., Cao, K., Guo, B., Xiang, J., Dong, Y., Qi, X., Yu, W., Xiao, Y. C., & Guan, Z. (2020) · Aging · doi:10.18632/aging.103435 · Cited by 23
Research Progress on the Pathogenesis, Diagnosis, and Drug Therapy of Alzheimer’s Disease
Yang, Y., & Qiu, L. (2024) · Brain Sciences · doi:10.3390/brainsci14060590 · Cited by 23
Wang, J., Du, L., Zhang, T., Chu, Y., Wang, Y., Wang, Y. T., Ji, X., Kang, Y., Cui, R., Zhang, G., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110006 · Cited by 23
Candelise, N., Santilli, F., Fabrizi, J., Caissutti, D., Spinello, Z., Moliterni, C., Lancia, L., Monache, S. D., Mattei, V., & Misasi, R. (2023) · Cells · doi:10.3390/cells12131686 · Cited by 23
Improvement of Key Molecular Events Linked to Alzheimer’s Disease Pathology Using Postbiotics
Bulacios, G. A., Cataldo, P. G., Naja, J. R., Chaves, E., Taranto, M. P., Minahk, C. J., Hebert, E. M., & Saavedra, L. (2023) · ACS Omega · doi:10.1021/acsomega.3c06805 · Cited by 23
Hu, Y., Chen, X., Zhang, Y., McGurran, H., Stormmesand, J., Breeuwsma, N., Sluiter, A. A., Zhao, J., Swaab, D. F., & Bao, A. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1117584 · Cited by 23
Protein aggregation and neurodegenerative disease: Structural outlook for the novel therapeutics
Arar, S. H., Haque, M. A., & Kayed, R. (2023) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26561 · Cited by 23
The endocrine pancreas of old obesehyperglycemic mice.
Westman, S. (1968) · PubMed · Cited by 23
A review of the auditory-gut-brain axis
Graham, A. S., Ben‐Azu, B., Tremblay, M., Torre, P., Senekal, M., Laughton, B., van der Kouwe, A. J. W., Jankiewicz, M., Kaba, M., & Holmes, M. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1183694 · Cited by 23
Schmitz, T. W., & Záborszky, L. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819975-6.00008-x · Cited by 23
Liu, Z., Qin, G., Mana, L., Dong, Y., Huang, S., Wang, Y., Wu, Y., Shi, J., Tian, J., & Wang, P. (2020) · Brain and Behavior · doi:10.1002/brb3.1602 · Cited by 23
Solà, E., Moyano, P. M., Flores, A., García, J. M., García, J., Anadón, M. J., Frejo, M. T., Pelayo, A., Fernández, M. D. L. C., & del Pino, J. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110428 · Cited by 23
The Role of Tau Pathology in Alzheimer’s Disease and Down Syndrome
Granholm, A., & Hamlett, E. D. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051338 · Cited by 23
Liang, Z., Li, X., Luo, X., Luo, H.-J., Chen, Y., Cai, M., Zhong, X.-X., Fang, Y., Guo, T., Shi, Y., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.02.018 · Cited by 23
The synthesis and bioactivity of apigenin derivatives
Liu, S., Zheng, X., Luo, Z., Tang, C., Hu, Y., Peng, Q., Mi, P., Chen, H., & Xu, Y. (2024) · Fitoterapia · doi:10.1016/j.fitote.2024.106228 · Cited by 23
Zhang, Z., Zhang, S., Wu, C., Li, H., Zha, L., Shi, J., Liu, X., Qin, H., & Tang, W. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115502 · Cited by 23
Interactions between functional networks in Parkinson's disease mild cognitive impairment
Delgado‐Alvarado, M., Ferrer-Gallardo, V. J., Paz‐Alonso, P. M., Caballero‐Gaudes, C., & Rodríguez-Oroz, M. C. (2023) · Scientific Reports · doi:10.1038/s41598-023-46991-3 · Cited by 23
Fitzgerald, G. S., Chuchta, T. G., & McNay, E. C. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14160 · Cited by 22
Ren, J., & Xiao, H. (2023) · Life · doi:10.3390/life13122285 · Cited by 22
The role of microRNAs in understanding sex-based differences in Alzheimer’s disease
Llera-Oyola, J., Carceller, H., Andreu, Z., Hidalgo, M. R., Soler-Sáez, I., Gordillo, F., Porlan, A., Pozo‐Morales, M., Beatriz, R., de la Iglesia-Vayá, M., et al. (2024) · Biology of Sex Differences · doi:10.1186/s13293-024-00588-1 · Cited by 22
Anni, D., Weiss, E., Guhathakurta, D., Akdaş, E. Y., Klueva, J., Zeitler, S., Andres‐Alonso, M., Huth, T., & Fejtová, A. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03835-5 · Cited by 22
David, M., & Malhotra, P. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51539 · Cited by 22
The Evolution of AChE Inhibitors in Alzheimer's Disease: From Single‐Target to Multi‐Target Ligands
Mehta, N. V., Kapadia, A., Khambete, M., & Abhyankar, A. N. (2025) · ChemBioChem · doi:10.1002/cbic.202500053 · Cited by 22
Amadoro, G., Latina, V., Stigliano, E., & Micera, A. (2023) · Cells · doi:10.3390/cells12222601 · Cited by 22
Vijayraghavan, S., & Everling, S. (2021) · Frontiers in Neural Circuits · doi:10.3389/fncir.2021.648624 · Cited by 22
Panek, D., Pasieka, A., Latacz, G., Zaręba, P., Szczęch, M., Godyń, J., Chantegreil, F., Nachon, F., Brazzolotto, X., Skrzypczak-Wiercioch, A., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115135 · Cited by 22
Cholinergic basal forebrain neurons regulate vascular dynamics and cerebrospinal fluid flux
Chuang, K., Zhou, X. A., Xia, Y., Li, Z., Qian, L., Eeles, E. M., Ngiam, G., Fripp, J., & Coulson, E. J. (2025) · Nature Communications · doi:10.1038/s41467-025-60812-3 · Cited by 22
Huperzine A: a natural acetylcholinesterase inhibitor with multifunctional neuroprotective effects
Suvaiv, Singh, K., Hasan, S. S., Kumar, R., Khan, A., Shahanawaz, M., Zaidi, S. M. H., & Verma, K. (2025) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-025-00675-1 · Cited by 22
The basal forebrain cholinergic system as target for cell replacement therapy in Parkinson’s disease
Björklund, A., & Barker, R. A. (2024) · Brain · doi:10.1093/brain/awae026 · Cited by 22
Mi, J., He, Y., Yang, J., Zhou, Y., Zhu, G., Wu, A., Liu, W., & Sang, Z. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128574 · Cited by 22
Wang, Y., Wei, X., Wang, H., Zhang, Y., Li, P., Zhou, Y., Jiang, S., Yan, R., Chen, L., & Zhao, H. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156882 · Cited by 22
Alzheimer’s disease: from early pathogenesis to novel therapeutic approaches
Prajapati, S. K., Pathak, A., & Samaiya, P. K. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01389-6 · Cited by 21
“These involvements have led to the proposal of the cholinergic hypothesis of AD (Babic 1999 ; Hampel et al. 2018 , 2019 ).”
Gao, Z., Wang, Y., & Yu, H. (2022) · Medicina · doi:10.3390/medicina59010055 · Cited by 21
Symptoms and conventional treatments of Alzheimer's disease
Chorawala, M. R., Shah, A. C., Pandya, A. J., Kothari, N. R., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00009-1 · Cited by 21
Niu, Q., Li, D., Zhang, J., Piao, Z., Xi, Y., Xi, Y., Kamal, N. N. S. N. M., Lim, V., Li, P., & Yin, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102593 · Cited by 21
The Role of Dietary Antioxidants and Their Potential Mechanisms in Alzheimer’s Disease Treatment
Knight, E., Geetha, T., Broderick, T. L., & Babu, J. R. (2023) · Metabolites · doi:10.3390/metabo13030438 · Cited by 21
Dual-target inhibitors of cholinesterase and GSK-3β to modulate Alzheimer’s disease
He, J., & Tam, K. Y. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103914 · Cited by 21
Dong, X., & Qu, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.877872 · Cited by 21
Zhang, Y. C., Li, Z., Guan, H., Qiu, Z., & Zou, C. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70548 · Cited by 21
Unearthing of Key Genes Driving the Pathogenesis of Alzheimer’s Disease via Bioinformatics
Zhao, X., Yao, H., & Li, X. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.641100 · Cited by 21
Lancour, D., Dupuis, J., Mayeux, R. P., Haines, J. L., Pericak‐Vance, M. A., Schellenberg, G. D., Crovella, M. E., Farrer, L. A., & Kasif, S. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00674-7 · Cited by 21
Peripheral transcriptomic biomarkers for early detection of sporadic Alzheimer disease?
Hadar, A., & Gurwitz, D. (2018) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2018.20.4/dgurwitz · Cited by 21
Shammari, L. A. A., Hulcová, D., Maříková, J., Kučera, T., Šafratová, M., Nováková, L., Schmidt, M., Pulkrabkova, L., Janoušek, J., Soukup, O., et al. (2020) · South African Journal of Botany · doi:10.1016/j.sajb.2020.06.024 · Cited by 21
Shaikh, S., Dhavan, P. P., Singh, P. R., Uparkar, J. J., Vaidya, S. P., Jadhav, B. L., & Ramana, M. M. V. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.2006088 · Cited by 21
Stanciu, G. D., Ababei, D. C., Solcan, C., Bild, V., Ciobîcă, A., Chiriac, S. I. B., Ciobanu, L., & Tamba, B.-I. (2023) · Pharmaceuticals · doi:10.3390/ph16111620 · Cited by 21
Khan, Y., Mukhtiar, A., Sarfraz, H., Khan, S. A., Hussain, R., Naeem, M., Sattar, A., Aziz, T. A., Panizai, Z. U. R., Albekairi, T. H., et al. (2025) · Zeitschrift für Naturforschung C · doi:10.1515/znc-2024-0244 · Cited by 21
Side effects and cognitive benefits of buspirone: A systematic review and meta-analysis
Du, Y., Li, Q., Dou, Y., Wang, M., Wang, Y., Yan, Y., Fan, H., Yang, X., & Ma, X. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28918 · Cited by 21
Macht, V. A., Vetreno, R. P., & Crews, F. T. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.849997 · Cited by 21
Patel, S., Jain, S., Gururani, R., Sharma, S. K., & Dwivedi, J. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03186-3 · Cited by 21
Neurodegenerative diseases and brain delivery of therapeutics: Bridging the gap using dendrimers
Kaur, A., Singh, N., Kaur, H., Kakoty, V., Sharma, D. S., Khursheed, R., Babu, M. R., Harish, V., Gupta, G., Gulati, M., et al. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104868 · Cited by 21
Aydın, S., Kabaoglu, I., Güler, E., Topal, F., Hazar‐Yavuz, A. N., Ekentok, C., Tatar, E., Gurbuz, F., Gündüz, O., & Çam, M. E. (2022) · Macromolecular Materials and Engineering · doi:10.1002/mame.202100855 · Cited by 21
Zhou, C., Feng, X., Liu, H., Cai, T., Li, Y., & Fan, H. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1593854 · Cited by 20
Jie, X., Ran, L., Zeng, X., He, W., Xu, Y., Cao, K., Dong, Y., Qi, X., Yu, W., Xiao, Y. C., et al. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17006 · Cited by 20
Çınar, E., Mutluay, S. U., Baysal, İ., Gültekinoğlu, M., Ulubayram, K., Ciftci, S. Y., Tel, B. C., & Uçar, G. (2022) · Nöro Psikiyatri Arşivi · doi:10.29399/npa.28275 · Cited by 20
Longitudinal GluCEST MRI Changes and Cerebral Blood Flow in 5xFAD Mice
Igarashi, H., Ueki, S., Kitaura, H., Kera, T., Ohno, K., Ohkubo, M., Terumitsu‐Tsujita, M., Kakita, A., & Kwee, I. L. (2020) · Contrast Media & Molecular Imaging · doi:10.1155/2020/8831936 · Cited by 20
Interval timing is disrupted in female 5xFAD mice: An indication of altered memory processes
Gür, E., Fertan, E., Alkins, K., Wong, A. A., Brown, R. E., & Balcı, F. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24418 · Cited by 20
Wu, D., Yu, N., Gao, Y., Xiong, R., Liu, L., Lei, H., Jin, S., Liu, J., Liu, Y., Xie, J., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00614-7 · Cited by 20
Tremendous Fidelity of Vitamin D3 in Age-related Neurological Disorders
Skv, M., Abraham, S. M., Eshwari, O., Golla, K., Jhelum, P., Maity, S., & Komal, P. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-03989-w · Cited by 20
Gupta, S., Dinesh, S., & Sharma, S. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249271548231115071021 · Cited by 20
Moftah, H. K., Mousa, M. H. A., Elrazaz, E. Z., Kamel, A. S. E. D., Lasheen, D. S., & Georgey, H. H. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107065 · Cited by 20
Mitochondrial Interaction with Serotonin in Neurobiology and Its Implication in Alzheimer’s Disease
Tian, J., Du, E. Y., & Guo, L. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230070 · Cited by 20
Takomthong, P., Waiwut, P., Yenjai, C., Sombatsri, A., Reubroycharoen, P., Lei, L., Lai, R., Chaiwiwatrakul, S., & Boonyarat, C. (2021) · Pharmaceuticals · doi:10.3390/ph14090888 · Cited by 20
Targeting immunoproteasome in neurodegeneration: A glance to the future
Tundo, G. R., Cascio, P., Milardi, D., Santoro, A. M., Graziani, G., Lacal, P. M., Bocedi, A., Oddone, F., Parravano, M., Coletta, A., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108329 · Cited by 21
Foffani, G. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad442 · Cited by 20
Hippocampal replay sequence governed by spontaneous brain-wide dynamics
Yang, Y., Leopold, D. A., Duyn, J. H., & Liu, X. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgae078 · Cited by 20
Nagamatsu, S. T., Rompala, G. R., Hurd, Y. L., Núñez-Ríos, D. L., & Montalvo‐Ortiz, J. L. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1078894 · Cited by 20
Tsimpili, H., & Zoidis, G. (2025) · Pharmaceuticals · doi:10.3390/ph18030369 · Cited by 20
Sıcak, Y., Kekeçmuhammed, H., Karaküçük‐İyidoğan, A., Taşkın‐Tok, T., Oruç‐Emre, E. E., & Öztürk, M. (2023) · Journal of Molecular Recognition · doi:10.1002/jmr.3020 · Cited by 20
Jalil, S., Basri, R., Aziz, M., Shafiq, Z., Ejaz, S. A., Hameed, A., & Iqbal, J. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.137841 · Cited by 20
Nucleus basalis of Meynert predicts cognition after deep brain stimulation in Parkinson's disease
Kübler, D., Wellmann, S. K., Kaminski, J. A., Skowronek, C., Schneider, G., Neumann, W., Ritter, K., & Kühn, A. A. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.12.002 · Cited by 20
Pathogenesis, Animal Models, and Drug Discovery of Alzheimer’s Disease
Xia, Z.-D., Ma, R.-X., Wen, J.-F., Zhai, Y.-F., Wang, Y.-Q., Wang, F.-Y., Liu, D., Zhao, X.-L., Sun, B., Jia, P., et al. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-230326 · Cited by 19
Soto‐Mercado, V., Mendivil‐Perez, M., Jiménez-Del-Río, M., & Velez‐Pardo, C. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201045 · Cited by 19
Ishola, I. O., Olubodun-Obadun, T. G., Ojulari, M. A., & Adeyemi, O. O. (2020) · Drug metabolism and drug interactions · doi:10.1515/dmdi-2020-0118 · Cited by 19
Xu, T., Chen, Z., Zhou, X., Wang, L., Zhou, F., Yao, D., Zhou, B., & Becker, B. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2306936121 · Cited by 19
Navarro‐Hortal, M. D., Romero‐Márquez, J. M., Osta, S., Jiménez-Trigo, V., Muñoz-Ollero, P., & Varela‐López, A. (2022) · Diseases · doi:10.3390/diseases10020028 · Cited by 19
Wang, J., Yu, Z., Ye, P., & Xu, B. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109397 · Cited by 19
Kundo, N. K., Manik, M. I. N., Biswas, K., Khatun, M. R., Al-Amin, M. Y., Alam, A. H. M. K., Tanaka, T., & Sadik, G. (2021) · BioMed Research International · doi:10.1155/2021/9154406 · Cited by 19
Targets, trials and tribulations in Alzheimer therapeutics
Gharat, R., Dixit, G., Khambete, M., & Prabhu, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176230 · Cited by 19
Park, J., Kim, S. H., Kim, Y. J., Kim, I. H., Oh, Y., Choi, K. Y., Kim, B. C., Lee, K. H., & Song, W. K. (2022) · Brain Research · doi:10.1016/j.brainres.2022.147924 · Cited by 19
Applications of Limonene in Neoplasms and Non-Neoplastic Diseases
Rakoczy, K., Szymańska, N., Stecko, J., Kisiel, M., Maruszak, M., Niedziela, M., & Kulbacka, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136359 · Cited by 19
Pifferi, F., Epelbaum, J., & Aujard, F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01291 · Cited by 19
Teixeira, F. C., Soares, M. S. P., Blödorn, E. B., Domingues, W. B., Reichert, K. P., Zago, A. M., Carvalho, F. B., Gutierres, J. M., Gonçales, R. A., Fernandes, M. D. C., et al. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02627-z · Cited by 19
A Review of Rattlesnake Venoms
Phan, P., Deshwal, A., McMahon, T. A., Slikas, M., Andrews, E., Becker, B. M., & Kumar, T. K. S. (2023) · Toxins · doi:10.3390/toxins16010002 · Cited by 19
Žužek, M. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25169049 · Cited by 19
Spatial distributions of cholinergic impairment and neuronal hypometabolism differ in MCI due to AD
Richter, N., Nellessen, N. D., Dronse, J., Dillen, K. N. H., Jacobs, H. I. L., Langen, K., Dietlein, M., Kracht, L., Neumaier, B., Fink, G. R., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101978 · Cited by 19
Cholinergic signaling to CA1 astrocytes controls fear extinction
Li, Y., Li, L., Wang, Y., Li, X., Ding, X., Li, L., Fei, F., Zheng, Y., Li, C., Duan, S., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads7191 · Cited by 19
L'organigramme du personnel d'une carrière impériale d'après un ostracon du Mons Claudianus
Cuvigny, H. (2017) · Chiron. Mitteilungen der Kommission für Alte Geschichte und Epigraphik des Deutschen Archäologischen Instituts · doi:10.34780/0m2y-2m9b · Cited by 19
The Convergence of Alzheimer’s Disease Pathogenesis Concepts
Kozin, S. A., & Makarov, A. А. (2019) · Molecular Biology · doi:10.1134/s0026893319060104 · Cited by 19
Valu, M.-V., DUCU, C. M., Moga, S. G., Negrea, D. A., Hriţcu, L., Boiangiu, R. Ş., Vamanu, E., Bălşeanu, T. A., Carradori, S., & Soare, L. C. (2021) · Pharmaceuticals · doi:10.3390/ph14060568 · Cited by 19
Mehrnoosh, F., Rezaei, D., Pakmehr, S., Nataj, P. G., Sattar, M., Shadi, M., Ali‐Khiavi, P., Zare, F., Hjazi, A. M., Al-Aouadi, R. F. A., et al. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01610-0 · Cited by 19
Acetylcholine Receptor Stimulation for Cognitive Enhancement: Better the Devil You Know?
Baxter, M. G., & Crimins, J. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.06.018 · Cited by 19
Urine biomarkers for Alzheimer's disease: A new opportunity for wastewater-based epidemiology?
Armenta-Castro, A., Núñez-Soto, M. T., Rodríguez-Aguillón, K. O., Aguayo-Acosta, A., Oyervides-Muñoz, M. A., Snyder, S. A., Barceló, ., Saththasivam, J., Lawler, J., Sosa‐Hernández, J. E., et al. (2024) · Environment International · doi:10.1016/j.envint.2024.108462 · Cited by 19
Elkader, H. A. E. A., Hussein, M. M., Mohammed, N. A., & Abdou, H. M. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02887-7 · Cited by 19
Deng, Y., Feng, Y., Lv, Z., He, J., Chen, X., Wang, C., Yuan, M., Xu, T., Gao, W., Chen, D., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.994130 · Cited by 19
Jiménez-Baladó, J., Herrera, A. Y., Igwe, K. C., Klem, L., Buyukturkoglu, K., Irimia, A., Liu, C., Guo, J., Brickman, A. M., & Eich, T. S. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.695416 · Cited by 19
Metadata
- Authors
- Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., & Khachaturian, Z. S.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Northwestern University (US)
- McGill University (CA)
- Indiana University School of Medicine (US)
- University Hospital of Geneva (CH)
- Saint Louis University (US)
- Prevent Alzheimer’s Disease 2020 (US)
- University of Rhode Island (US)
- Corresponding author
- Hampel, Harald
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-05-29
- Volume
- 141
- Issue
- 7
- Pages
- 1917-1933
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6022632
- OpenAlex
- W2805257646
- Cited by
- 1,918
- References
- 179
- Citations by year
- 2026: 245 · 2025: 298 · 2024: 298 · 2023: 328 · 2022: 300 · 2021: 228 · 2020: 130 · 2019: 65 · 2018: 21
- FWCI
- 14.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Brain (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- Funders
- AXA Research Fund
- ‘Fondation pour la Recherche sur Alzheimer’, Paris, France. Ce travail a bénéficié d'une aide de l’Etat ‘Investissements d’avenir’ (ANR-10-IAIHU-06)
- ‘Investissements d’avenir’ (ANR-10-IAIHU-06)
- Canadian Institutes of Health Research
- National Research Council
- Alzheimer Society of Canada
- Rotary Club Livorno ‘Mascagni’/The Rotary Foundation (GG1758249)
- ADC (AG013854)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, cholinergic system, cholinergic hypothesis, cholinesterase inhibitors, acetylcholine, cholinergic denervation, neurofibrillary degeneration, amyloid plaques, cognitive decline, cholinergic drugs, combination therapy
- MeSH terms
- Alzheimer Disease, Cholinesterase Inhibitors, Cognition, Cognition Disorders, Humans, Amyloid beta-Peptides, Neurofibrillary Tangles, Cholinergic Agents, Cholinergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.